Abeona Therapeutics Inc. (NASDAQ:ABEO – Get Free Report) Director Mark Alvino sold 15,000 shares of Abeona Therapeutics stock in a transaction on Tuesday, September 1st. The shares were sold at an average price of $5.86, for a total value of $87,900.00. Following the completion of the transaction, the director owned 62,065 shares of the company’s stock, valued at approximately $363,700.90. The trade was a 19.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Abeona Therapeutics Price Performance
Shares of ABEO stock opened at $5.95 on Thursday. The stock’s fifty day moving average is $6.42 and its 200-day moving average is $5.66. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.40 and a current ratio of 6.63. The stock has a market capitalization of $340.22 million, a PE ratio of -5.46 and a beta of 1.33. Abeona Therapeutics Inc. has a 52 week low of $4.00 and a 52 week high of $7.65.
Abeona Therapeutics (NASDAQ:ABEO – Get Free Report) last announced its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.12). The firm had revenue of $11.38 million during the quarter, compared to the consensus estimate of $12.24 million. Equities research analysts expect that Abeona Therapeutics Inc. will post -0.93 EPS for the current fiscal year.
Institutional Trading of Abeona Therapeutics
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on the stock. Wall Street Zen upgraded shares of Abeona Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 1st. Weiss Ratings cut shares of Abeona Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 17th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, May 28th. Finally, Oppenheimer restated an “outperform” rating and set a $21.00 target price (down from $22.00) on shares of Abeona Therapeutics in a research report on Friday, August 14th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.33.
Check Out Our Latest Research Report on Abeona Therapeutics
About Abeona Therapeutics
Abeona Therapeutics is a clinical‐stage biopharmaceutical company focused on the development and commercialization of gene and cell therapies for severe, life‐threatening rare diseases and oncology indications. Founded in 2014 and headquartered in Cleveland, Ohio, Abeona leverages proprietary viral and non‐viral delivery platforms to correct or compensate for underlying genetic deficiencies. The company’s research efforts target pediatric neurodegenerative disorders as well as debilitating dermatologic conditions with high unmet medical need.
The company’s lead clinical programs include separate AAV‐based gene therapies for CLN1 and CLN3 forms of neuronal ceroid lipofuscinosis, alongside an ex vivo autologous cell therapy for recessive dystrophic epidermolysis bullosa.
Read More
- Five stocks we like better than Abeona Therapeutics
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
